[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Subscription::
Contact us::
Site Facilities::
::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Last site contents
:: Editorial Board
:: About Iranian Journal of Endocrinology and Metabolism
:: Volume 4, Issue 1 (3-2002) ::
2002, 4(1): 15-21 Back to browse issues page
Effect of pharmacologic doses of vitamin C on glycosylated hemoglobin in type 2 diabetic patients
S Darvish Moghaddam , GH Moshtaghi Kashanian , M Hayatbakhsh , A Mehdipour
, sdmoghaddam@yahoo.com
Abstract:   (29477 Views)
Introduction: Formation of end-glycation products is one of the major causes of chronic diabetes complications. Although there is some evidence that vitamin C inhibits protein and hemoglobin glycosylation in healthy individuals, its effect on diabetic patients is still being debated. The aim of this clinical trial was to examine the pharmacologic effect of vitamin C on hemoglobin A1c (HbA1c) and fasting blood sugar (FBS plasma levels) in diabetic patients. Materials and Methods: For this purpose 53 (8 male, 45 female) type 2 diabetic patients who had FBS <250 mg/dL were selected for the study. The age range was 37-70 years with a mean of 52.8±10 years. Patients were given 1g vitamin C per day for 3 months. Changes in body weight, FBS, and HbA1c level were compared before and after therapy. FBS was measured by the enzymatic glucose oxidase method (normal range: 75-110 mg/dL) and HbA1c was assayed according to WHO calorimetric method with a normal range of 2.5-4 μmol/g Hb%. Results: The mean FBS level was 185±43.9 mg/dL at the beginning and 176.5± 48.7 mg/dL at the end of study. The mean FBS level changes during study was -8.9±40.2 mg/dL, which was not significant (p>0.05). The mean HbA1c level at the beginning was 4.9± 0.9, at the end 4.7±1, with a mean change of range -0.2±0.9 μmol/gHb%, which was not significant (p>0.05). Also mean body weight changes were not significant during study (p>0.05). The decrease in level of HbA1c from 1 to 15%, shown in 49% of patients was related significantly to decreased weight (p<0.001) and in the 26% with most decreased HbA1c levels (10-15%), it was related also to decreased FBS (p<0.05). Conclusion: According to these results, decreased HbA1c level was due to weight loss and better glucose control rather than vitamin C effects. Therefore vitamin C consumption for prevention of type 2 diabetes complications by inhibition of protein glycosylation is not recommended.
Keywords: Type 2 diabetes, Vitamin C, Fasting blood sugar, HbA1c
Full-Text [PDF 281 kb]   (4216 Downloads)    
Type of Study: Original | Subject: Endocrinology
Received: 2006/11/21 | Published: 2002/03/15
Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Darvish Moghaddam S, Moshtaghi Kashanian G, Hayatbakhsh M, Mehdipour A. Effect of pharmacologic doses of vitamin C on glycosylated hemoglobin in type 2 diabetic patients. Iranian Journal of Endocrinology and Metabolism 2002; 4 (1) :15-21
URL: http://ijem.sbmu.ac.ir/article-1-174-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 4, Issue 1 (3-2002) Back to browse issues page
مجله ی غدد درون‌ریز و متابولیسم ایران، دو ماهنامه  پژوهشی مرکز تحقیقات غدد درون‌ریز و متابولیسم، Iranian Journal of Endocrinology and Metabolism
Persian site map - English site map - Created in 0.07 seconds with 38 queries by YEKTAWEB 4642